相关实验视频

Updated: Jul 8, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

22.0K

TSCM-主导的全基抗BCMACAR-T治疗复发性/耐药性多发性骨髓瘤:临床前表征和1期试验的临时结果

Hubert Tseng1, Bhagirathbhai Dholaria2, Stacey A Cranert1

  • 1Poseida Therapeutics, Inc, San Diego, CA, USA.

Nature communications
|November 24, 2025
PubMed
概括

针对BCMA的异构CAR-T疗法在复发性/耐药性多发性髓瘤中显示出前景. 在早期临床试验中,T_SCM 主导的P-BCMA-ALLO1显示出高响应率和良好的安全性.

更多相关视频

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

15.4K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.7K

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.